FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for teriparatide filed by Prasco Laboratories, expanding the regulatory status of the product under NDA021318.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucocorticoid-induced Osteoporosis
• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Teriparatide (Teriparatide)

Snippet

SUPPL AP for TERIPARATIDE (TERIPARATIDE)